and acid via CLA (2). Over the past decade, research from several laboratories has shown that CLA expresses powerful activity Joseph A.Scimeca 3 in cancer protection in a number of animal models (3-7). conceivably rendering the target cell population less susceptible A major objective of this study was to evaluate how changes to carcinogen-induced neoplastic transformation (8,9). Second, in the concentration of CLA in mammary tissue as a CLA is also capable of inhibiting tumor promotion/progression function of CLA exposure/withdrawal were correlated with (9); however, a continuous supply of CLA is required for this the rate of occurrence of mammary carcinomas. Rats mechanism of action.
CLA appears to have a dual effect in the modulation of mammary carcinogenesis in rats. First, exposure to CLA during 1 To whom correspondence should be addressed the window of active mammary gland morphogenesis may Conjugated linoleic acid (CLA) has been reported to have reduce the proliferation of epithelial end bud cells, thus significant activity in inhibiting mammary carcinogenesis.
conceivably rendering the target cell population less susceptible A major objective of this study was to evaluate how changes to carcinogen-induced neoplastic transformation (8,9). Second, in the concentration of CLA in mammary tissue as a CLA is also capable of inhibiting tumor promotion/progression function of CLA exposure/withdrawal were correlated with (9); however, a continuous supply of CLA is required for this the rate of occurrence of mammary carcinomas. Rats mechanism of action.
treated with a single dose of dimethylbenz[a]anthracene
The above study regarding the effectiveness of CLA in (DMBA) at 50 days of age were given 1% CLA in the diet blocking tumor progression was carried out in the methylnitrofor either 4 weeks, 8 weeks or continuously following sourea (MNU)-induced mammary carcinogenesis model in rats carcinogen administration. No cancer protection was evidfed a 5% corn oil diet (9). One objective of the experiments ent in the 4 or 8 week-CLA treatment groups. Significant reported in this study was to confirm the necessity of maintumor inhibition was observed only in rats that were given taining CLA intake after cancer induction by using dimethyl-CLA for the entire duration of the experiment (20 weeks).
benz [a] anthracene (DMBA)-treated rats fed a 20% corn oil Analysis of CLA in the mammary gland showed that the diet. It was considered important to assess whether the requireincorporation of CLA was much higher in neutral lipids ment for continuous CLA feeding was dependent on the nature than in phospholipids. When CLA was removed from the of the carcinogen and the fat content of the diet. Rats were diet, neutral lipid-and phospholipid-CLA returned to basal therefore given CLA for a duration of either 4, 8 or 20 weeks, values in about 4 and 8 weeks, respectively. The rate of starting immediately after a single dose of DMBA, to evaluate disappearance of neutral lipid-CLA (rather than phospholithe anti-carcinogenic efficacy of these various intervention pid-CLA) subsequent to CLA withdrawal paralleled more regimens. The kinetics of mammary tissue CLA retention as closely the rate of occurrence of new tumors in the target a function of CLA exposure/withdrawal was also analyzed in tissue. It appears that neutral lipid-CLA may be a more order to determine the correlation between time-dependent sensitive marker of tumor protection than phospholipidchanges in tissue concentrations of CLA and effectiveness of CLA. However, the physiological relevance of CLA accumucancer protection. lation in mammary lipids is unclear and remains to be Additionally, we were interested in finding out whether determined. A secondary goal of this study was to investi-CLA might selectively inhibit the clonal expansion of DMBAgate whether CLA might selectively inhibit clonal expansion initiated cells carrying either the wild type or codon 61 mutated of DMBA-initiated mammary epithelial cells with wildHa-ras gene. Previous work from Thompson's laboratory has type versus codon 61 mutated Ha-ras genes. Approximately shown that high dietary levels of linoleic acid preferentially 16% of carcinomas in the control group (without CLA) increased the number of wild type Ha-ras mammary tumors, were found to express codon 61 ras mutation. Although but not the codon 12 mutant Ha-ras tumors, in the rat MNU continuous treatment with CLA reduced the total number model (10). In chemical carcinogenesis, specific ras mutations of carcinomas by 70%, it did not alter the proportion of are induced and are believed to be involved in early stages ras mutant versus wild-type carcinomas, suggesting that of tumor development (11-14). Generally, ras mutation is CLA inhibits mammary carcinogenesis irrespective of the considered to be permissive but not sufficient for carcinopresence or absence of the ras mutation.
genesis. Thus the ras genotype was used as a marker in the present study to identify subpopulations of neoplastically transformed cells that might be differentially modulated by Introduction CLA intervention. Conjugated linoleic acid (CLA*) is a minor fatty acid found preferentially in red meat and dairy products (1) . The biosynMaterials and methods thesis of CLA in ruminants is accounted for by a rumen Pathogen-free female Sprague-Dawley rats were purchased from Charles bacterium, which is known to convert linoleic acid to stearic River Breeding Laboratories at 45 days of age. They were fed a 20% corn oil diet (6) and were intubated with a single dose of 10 mg of DMBA at 50 days of age for the induction of mammary tumors. Supplementation of CLA *Abbreviations: CLA, conjugated linoleic acid; DMBA, dimethylbenz[a]anthracene; MNU, methylnitrosourea; PCR/RFLP, polymerase chain (Nu-Chek, Elysian, MN) at 1% in the diet was started 4 days after carcinogen administration. A total of 90 rats were given CLA and were divided equally reaction-generated restriction fragment length polymorphism. a These tumors were harvested from the mammary carcinogenesis experiment described in Figure 1 .
into three groups according to the length of CLA treatment: 4 weeks, 8 weeks or continuously until the end of the experiment. Control rats (n ϭ 30) were not given CLA at any time during the study. Animals were palpated weekly for mammary tumors; the time of appearance and location of tumors in the mammary gland were recorded. The experiment Fig. 1 . Effect of interrupted versus continuous CLA feeding after DMBA was terminated 20 weeks after DMBA. By that time, the development of administration on mammary carcinogenesis. The duration of CLA feeding in palpable tumors had plateaued for several weeks across all groups. Only the three supplemented groups is indicated along the x-axis time line by the histologically confirmed adenocarcinomas were reported in the results. Tumor filled symbols, which match the time course of mammary tumor incidences at the final time point were compared by chi squared analysis, and development on the main body of the diagram. Control group without CLA the total tumor yield between the control and CLA-treated groups was supplementation is represented by the open circle. The asterisk denotes compared by frequency distribution analysis as described previously (15). statistically significant difference (P Ͻ 0.05) from the control data. A total of 177 mammary adenocarcinomas were harvested from the above carcinogenesis bioassay. They were individually identified after excision so that each one could be tracked to its time of appearance in a particular rat. All 177 paraffin block-embedded tumors were analyzed for codon 61 ras mutation (CAA→CTA) by a modification of the polymerase chain reactiongenerated restriction fragment length polymorphism (PCR/RFLP) method as described by Kumar and Barbacid (16). Two 5-µ sections were prepared sideby-side from the same paraffin block, one mounted on a plastic slide, the other on a glass slide, which was subsequently stained with hematoxylin and eosin for the identification of tumor cell foci under the microscope. The exact same area of interest was matched on the plastic slide and was then cut out for DNA extraction (17). The primers used for PCR amplification were 5Ј-GAGACGTGTTTACTGGACATCTT-3Ј and 5Ј-GTGTTGTTGATGGCAAA-TACACAGAGG-3Ј (synthesized by Integrated DNA Technologies, Coralville, Fig. 2 . Detection of Ha-ras codon 61 CAA→CTA mutation by PCR/RFLP IA), which yielded a 116 bp PCR product (18,19). The PCR reaction mixture method. The mutation produces a XbaI site in amplified 116-bp DNA contained 5 µl of DNA extract, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 fragment. Upon separation of the XbaI-digested product in 6% mM MgCl 2 , 15 µM deoxynucleotide triphosphate, 1 µCi of α-[ 32 P]dCTP, 0.1 polyacrylamide gel, the presence of a 80-bp band (arrow) serves as a µM upstream and downstream primers, and 0.5 units AmpliTaq DNA diagnostic marker for the mutation. PCR products were labeled with tracer polymerase (Perkin-Elmer, Norwalk, CT). For each batch of PCR reaction, amount of α-[ 32 P]dCTP and detected by autoradiography. Lane B, blank PCR-grade H 2 O was used as a blank, DNA from a tumor bearing Ha-ras without template DNA; lane M, normal mammary gland DNA as a negative codon 61 mutation as a positive control, and DNA from normal mammary control; lane 1-16, mammary adenocarcinomas DNA. ϩ and -, 5 µl of gland as a negative control. Amplification was carried out for 40 cycles at: PCR product treated with or without 5 units of XbaI, respectively. 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min using a GeneAmp PCR system 9600 (Perkin-Elmer). The codon 61 A→T mutation introduces a Xba I restriction site into the 116 bp PCR product, which upon digestion, generates time. It can be seen that short-term feeding of CLA for only two fragments of 80 and 36 bp that are diagnostic for the mutation. In contrast, 4 or 8 weeks after DMBA administration was not effective in the PCR product of the normal gene contains a sequence that is not susceptible tumor inhibition. In the 8 week-CLA treatment group, the time to digestion by Xba I. The digested materials were separated by electrophoresis on a 6% polyacrylamide gel, and detected by autoradiography on X-ray film.
course curve was shifted slightly to the right, suggesting a
To study the kinetics of CLA retention in the mammary gland, a two-part delay of about 2 to 3 weeks in the appearance of tumors. experiment was conducted to examine (i) the rate of increase of tissue CLA However, as soon as CLA was withdrawn, the rate of tumor following the start of CLA feeding, and (ii) the rate of disappearance of tissue appearance resumed at a rapid pace. At the time of necropsy, CLA following CLA withdrawal. For the first part, 60-day-old rats (agematched to those in the above carcinogenesis experiment but not given the difference in tumor occurrence between the control group DMBA) were fed a 1% CLA diet and were killed at 1, 2, 4, 6 or 8 weeks and the 8 week-CLA treatment group was not statistically later. For the second part, rats were fed a 1% CLA diet for 8 weeks, the significant. In contrast, marked cancer protection, as judged treatment was discontinued and necropsy was timed at 1, 2, 4 or 6 weeks by a 50% reduction in tumor incidence and a 70% reduction after CLA withdrawal. Total lipid was extracted from the mammary gland by in the total number of tumors, was observed in rats that were chloroform/methanol. The separation of neutral lipids and phospholipids was achieved with the use of a Sep-Pak silica cartridge as described in an earlier given CLA for the entire duration of the study. publication (5). Gas chromatographic analysis of the CLA methyl ester was radiograms of XbaI digested PCR products from tumors with either the wild-type or codon 61 mutant ras gene. The arrow Results in the diagram indicates the presence of a 80-bp band, which is diagnostic for the mutation. Table I summarizes the frequency Figure 1 shows the time course of mammary tumor development in control rats or rats fed CLA for various lengths of distribution of both wild-type and mutant ras mammary 
Discussion
The present study confirms our previous report that a continucarcinomas from the above experiment. In the control group, ous supply of CLA is necessary for maximum tumor inhibition 16% of the tumors expressed the mutant ras gene. Continuous in the post-initiation phase of mammary carcinogenesis. As feeding of CLA reduced the total number of carcinomas by pointed out in the Introduction, the first experiment was done 70%, but was found to suppress approximately the same in MNU-treated rats fed a 5% corn oil diet (9), whereas the proportion of wild-type and mutant ras carcinomas in comparrepeat experiment described here was carried out in DMBAison with the control group. Short-term treatment with CLA treated rats fed a 20% corn oil diet. Thus this characteristic of for 4 or 8 weeks did not decrease significantly the total number CLA in chemoprevention is apparently not dependent on of carcinomas, nor did it alter markedly the distribution of specific genomic mutation induced at the time of initiation or carcinomas carrying either the wild-type or mutant ras gene.
the availability of linoleic acid fed to the animals during tumor Overall, there was no unusual pattern in the time of appearance progression. It might be instructive to contrast the effects of of the ras mutant tumors due to CLA intervention (data CLA and linoleic acid at this point. Our study here indicated not shown). Thus our results indicate that CLA inhibited that CLA inhibits mammary carcinogenesis irrespective of the carcinogenesis irrespective of the presence or absence of the presence or absence of ras mutation. Linoleic acid, on the codon 61 ras mutation.
other hand, has been demonstrated to promote selectively the Figure 3 shows the rates of CLA accumulation and disappeardevelopment of the wild type ras tumors, but not the mutant ance in the neutral lipid fraction of the mammary tissue ras tumors, in MNU-treated rats (10). Recent data also sugfollowing CLA administration and withdrawal. As the results gested that the response to CLA is unlikely to be due to a indicate, the incorporation was rapid once CLA was added to displacement of linoleic acid in the mammary tissue (20). the animals' diets. The level reached~70% of maximum after Collectively, the above information provides supportive evid-2 weeks of feeding, and plateaued after 4 weeks. At the peak, ence that these two fatty acids may have distinctive mechanisms CLA was present at roughly 3% of total fatty acids in the in the modulation of mammary carcinogenesis. neutral lipid fraction. In this experiment, some animals were Mutations of the ras gene have been reported to occur in a given CLA for 8 weeks. The regimen was stopped, and the target organ-and chemical carcinogen-specific manner in a decrease in CLA concentration was then plotted in the same number of experimental models (21). Zarbl et al. (22) have composite diagram. Figure 3 shows that as soon as CLA was previously described that in MNU-induced mammary tumors, discontinued, the rate of disappearance from the mammary GGA→GAA mutation in codon 12 of the Ha-ras prototissue was equally fast, with a return to basal value in about oncogene is a common event. The mutation probably results 4 weeks. from methylation of guanine by diazomethane, a spontaneous Figure 4 shows the increases and decreases of mammary decomposition product of MNU. In contrast, these same gland phospholipid CLA from the same experiment. It should investigators found that only 21% (three out of 14) of DMBAbe noted that during CLA supplementation, the concentration induced mammary tumors express a CAA→CTA mutation in of CLA in phospholipids (expressed as percent of total fatty codon 61 of the Ha-ras gene (22). It has been proposed that acids) was, on the average, an order of magnitude lower than the A→T transversion is probably due to the affinity of the the concentration in neutral lipids. Interestingly, the rate of DMBA diol epoxide to the adenine residue as well as to the change of phospholipid CLA in either the upswing or downsequence selectivity in binding of the metabolite to the Haswing of the exposure/withdrawal curve was slower compared ras DNA (23,24). To our knowledge, there has been one other with that observed with neutral lipid CLA. After the start of study examining Ha-ras codon 61 mutation in the DMBA CLA feeding, the maximum level in phospholipids was not model. Interestingly, Waldmann et al. (25) did not find such a attained until about 6 to 8 weeks later. Similarly, a diminished mutation in a total of 50 tumors. The relatively low incidence but still detectable amount of CLA was present by 6 weeks of Ha-ras codon 61 mutation in our study is similar to that reported by Zarbl et al. (22) . However, it should be noted that subsequent to the removal of CLA from the diet. any case, the data in Table I 
